SAN DIEGO, CA - October 3, 2013 - La Jolla Pharmaceutical Company (OTCBB: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company will present at the 12th Annual BIO Investor Forum, being held at the Palace Hotel in San Francisco, California on October 8-9, 2013. George F. Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla will present on La Jolla's recent progress including details of the recent financing and capital restructuring at 10:30am Pacific Time on Tuesday, October 8th in the Sea Cliff Room. The presentation will also be available via webcast on our website at http://www.ljpc.com.
About the BIO Investor Forum
The 12th Annual BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One partnering meetings.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501 is a product candidate for the treatment of hepatorenal syndrome. For more information on the Company please visit http://www.ljpc.com.
Forward Looking Statement Safe Harbor
This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), all of which are available free of charge on the SEC's web site http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100 and LJPC-501, the success and timing of future preclinical and clinical studies of these compounds, the use of proceeds from financings and potential indications for which GCS-100 and LJPC-501 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
La Jolla Pharmaceutical Company
Phone: (858) 207-4264
Chester S. Zygmont, III
Director of Finance
La Jolla Pharmaceutical Company
Phone: (858) 207-4262
SOURCE: La Jolla Pharmaceutical Company